ANTX Annual EBITDA
-$69.64 M
-$27.37 M-64.77%
31 December 2023
Summary:
As of January 23, 2025, ANTX annual earnings before interest, taxes, depreciation & amortization is -$69.64 million, with the most recent change of -$27.37 million (-64.77%) on December 31, 2023. During the last 3 years, it has fallen by -$62.35 million (-856.00%). ANTX annual EBITDA is now -856.00% below its all-time high of -$7.28 million, reached on December 31, 2020.ANTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANTX Quarterly EBITDA
-$11.77 M
+$4.11 M+25.88%
30 September 2024
Summary:
As of January 23, 2025, ANTX quarterly earnings before interest, taxes, depreciation & amortization is -$11.77 million, with the most recent change of +$4.11 million (+25.88%) on September 30, 2024. Over the past year, it has increased by +$6.53 million (+35.66%). ANTX quarterly EBITDA is now -474.20% below its all-time high of -$2.05 million, reached on March 31, 2021.ANTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANTX TTM EBITDA
-$64.76 M
+$6.41 M+9.01%
30 September 2024
Summary:
As of January 23, 2025, ANTX TTM earnings before interest, taxes, depreciation & amortization is -$64.76 million, with the most recent change of +$6.41 million (+9.01%) on September 30, 2024. Over the past year, it has increased by +$7.13 million (+9.92%). ANTX TTM EBITDA is now -3059.12% below its all-time high of -$2.05 million, reached on March 31, 2021.ANTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -64.8% | +35.7% | +9.9% |
| 3 y3 years | -856.0% | +35.7% | +9.9% |
| 5 y5 years | -856.0% | +35.7% | +9.9% |
ANTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -222.8% | at low | -55.0% | +37.4% | -200.2% | +9.9% |
| 5 y | 5-year | -856.0% | at low | -474.2% | +37.4% | -3059.1% | +9.9% |
| alltime | all time | -856.0% | at low | -474.2% | +37.4% | -3059.1% | +9.9% |
AN2 Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$11.77 M(-25.9%) | -$64.76 M(-9.0%) |
| June 2024 | - | -$15.88 M(-13.2%) | -$71.17 M(-1.0%) |
| Mar 2024 | - | -$18.30 M(-2.8%) | -$71.89 M(+3.2%) |
| Dec 2023 | -$69.64 M(+64.8%) | -$18.82 M(+3.5%) | -$69.64 M(+10.0%) |
| Sept 2023 | - | -$18.18 M(+9.5%) | -$63.30 M(+11.3%) |
| June 2023 | - | -$16.60 M(+3.5%) | -$56.89 M(+12.4%) |
| Mar 2023 | - | -$16.04 M(+28.6%) | -$50.62 M(+19.8%) |
| Dec 2022 | -$42.26 M | -$12.48 M(+6.0%) | -$42.26 M(+13.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$11.77 M(+13.9%) | -$37.38 M(+14.9%) |
| June 2022 | - | -$10.33 M(+34.5%) | -$32.54 M(+19.6%) |
| Mar 2022 | - | -$7.68 M(+1.2%) | -$27.21 M(+26.1%) |
| Dec 2021 | -$21.57 M(+196.2%) | - | - |
| Dec 2021 | - | -$7.59 M(+9.5%) | -$21.57 M(+54.3%) |
| Sept 2021 | - | -$6.93 M(+38.7%) | -$13.98 M(+98.4%) |
| June 2021 | - | -$5.00 M(+143.8%) | -$7.05 M(+243.8%) |
| Mar 2021 | - | -$2.05 M | -$2.05 M |
| Dec 2020 | -$7.28 M | - | - |
FAQ
- What is AN2 Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for AN2 Therapeutics?
- What is AN2 Therapeutics annual EBITDA year-on-year change?
- What is AN2 Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for AN2 Therapeutics?
- What is AN2 Therapeutics quarterly EBITDA year-on-year change?
- What is AN2 Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for AN2 Therapeutics?
- What is AN2 Therapeutics TTM EBITDA year-on-year change?
What is AN2 Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ANTX is -$69.64 M
What is the all time high annual EBITDA for AN2 Therapeutics?
AN2 Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$7.28 M
What is AN2 Therapeutics annual EBITDA year-on-year change?
Over the past year, ANTX annual earnings before interest, taxes, depreciation & amortization has changed by -$27.37 M (-64.77%)
What is AN2 Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ANTX is -$11.77 M
What is the all time high quarterly EBITDA for AN2 Therapeutics?
AN2 Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$2.05 M
What is AN2 Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ANTX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$6.53 M (+35.66%)
What is AN2 Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ANTX is -$64.76 M
What is the all time high TTM EBITDA for AN2 Therapeutics?
AN2 Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.05 M
What is AN2 Therapeutics TTM EBITDA year-on-year change?
Over the past year, ANTX TTM earnings before interest, taxes, depreciation & amortization has changed by +$7.13 M (+9.92%)